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Abstract 
 
Potentiation of the inotropic effect of isoproterenol by naloxone in 
vitro; non-opiate receptor mechanism 
 
Chul Ho Chang 
 
Department of Medicine 
The Graduate School, Yonsei University 
 
(Directed by Professor Wyun Kon Park) 
 
The aim of this study was to define the mechanism of non-opiate 
receptor-mediated action of naloxone, which potentiates the inotropic effect of 
isoproterenol on the myocardium.  Inotropic intervention, measurements of 
cyclic adenosine monophosphate (cAMP), and electrophysiological methods 
were used.  
 Cardiac papillary muscle of the right ventricle was obtained from male 
guinea pigs (300-400 g) under sevoflurane general anesthesia.  Peak force 
and maximum rate of force development (dF/dt-max) were measured.  
Cumulative concentration-response curves for isoproterenol as well as for 
forskolin and 3-isobutylmethylxanthine (IBMX) were obtained by increasing 
the concentration stepwise.  The enhancement of contraction by naloxone in 
the presence of isoproterenol was further confirmed by sequentially applying 
increasing concentrations of naloxone in the presence of EC50 values of 
isoproterenol as well as forskolin and IBMX.  For cAMP assays, cardiac 
muscle was homogenized and centrifuged to separate a membranous protein 
fraction.  Naloxone-induced changes in cAMP in the presence of EC50 
isoproterenol or forskolin were measured with cAMP assay kit.  In 
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electrophysiologic studies, action potential, delayed outward K+ current (Ik), 
inward rectifier K+ current (Ik1), and L-type Ca2+ current (ICa, L) were measured.  
 Naloxone (30 µM) produced a leftward shift of the isoproterenol 
concentration-response curve (0.01-2 µM).  While naloxone (30 µM) 
produced a leftward shift of the forskolin concentration-response curve (0.01-
2 µM) until 3 µM concentration, markedly enhanced contraction was 
observed from 10 to 30 µM concentration ranges.  Naloxone had no effect on 
the IBMX concentration-response curve.  Concentration-related 
enhancement of contractile forces following sequential application of 
naloxone (10, 30, and 300 µM) in the presence of isoproterenol was shown.   
Naloxone did not alter the cAMP levels induced by application of EC50 
isoproterenol or forskolin.  Naloxone (30 µM), in the presence of 
isoproterenol, prolonged APD50 and APD90 while the amplitude and resting 
membrane potential was unchanged.  Naloxone significantly reduced peak 
outward IK at +80 mV to 20±3% of isoproterenol-treated group, but did not 
alter the Ik1 from -140 mV to 0 mV.  At a membrane potential of +10 mV, 
naloxone reduced the ICa, L by 28±3%.  Thus, enhancement of myocardial 
contractility by naloxone in the presence of isoproterenol is, at least in part, 
likely due to inhibition of delayed outward K+ current, resulting in a 
secondary increase of inward Ca2+ current. 
______________________________________________________________  
Key words:  Naloxone, non-opioid receptor-mediated action, myocardial 
contractility, cAMP, delayed outward K+ current.  
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Ⅰ. INTRODUCTION 
 
Since the discovery of opioid peptides in 1975,1 the functional role of 
opiate receptors and their peptide ligands has been extensively researched.  
In 1978, Holaday and Faden2 provided the first experimental evidence of 
opioid peptide involvement in the physiology of septic shock in rat.  
Subsequent studies in several animal species supported the potential 
therapeutic efficacy of opioid antagonists, such as naloxone, in different 
experimental shock states such as endotoxic,2,3 hypovolemic,4,5 and spinal 
shock6,7.  Since then many papers have been published on the use of 
naloxone in human shock.8 Considering that naloxone administration has been 
documented to be beneficial in some patients, although conflicting clinical 
results still exist, naloxone still may be a useful adjunct in the treatment of 
patients with severe septic shock who are unresponsive to other resuscitative 
measures,8  
 In shock state, it has been postulated that naloxone generates the 
cardiovascular pressor effect by displacing the endogenous opiate-like peptide 
ß-endorphin, which is secreted in increased amounts from the 
adenohypophysis in response to acute stress and binds to the opiate receptors 
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of the myocardium, resulting in restoration of the normal response to 
catecholamines released during shock.9, 10 
 In addition to this opioid antagonistic effect of naloxone, an alternative 
mechanism of action, the non-opiate receptor-mediated effect, which 
potentiates the adrenergic effect, has been proposed.  Lechner11 in a study 
using guinea pig (GP) papillary muscles pretreated with isoproterenol, 
demonstrated that when muscles were exposed to either d-naloxone, the 
stereoisomer of l-naloxone which does not displace opioids from opiate 
receptors, or l-naloxone, there was a similar dose-dependent increase in 
contractility at concentrations of 10 and 30 µM, indicating that the non-opiate 
receptor-mediated properties predominate at these concentrations.  Such a 
non stereo-specific effect of naloxone in the presence of catecholamines has 
also been demonstrated in studies using isolated canine renal arteries12 and in 
situ-isolated heart/lung preparation in dogs.13  At present, although a non-
opiate receptor-mediated effect of naloxone has been proposed, the underlying 
mechanisms have not yet been defined.  The purpose of this study, therefore, 
was to elucidate the mechanism of naloxone’s non-opiate receptor-mediated 
action on the myocardium, using inotropic intervention, measurements of 
cyclic adenosine monophosphate (cAMP), and electrophysiological methods.  
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Ⅱ. MATERIALS AND METHODS  
 
1. Effects on contractility 
A.  Experiments with modified standard Tyrode solution   
 According to a procedure approved by the Yonsei University College 
of Medicine Animal Research Committee, the heart was removed from 350-
400 g male GPs following sevoflurane anesthesia (3-4 vol%).  The right 
ventricular papillary muscles were excised, mounted horizontally in a tissue 
bath, and superfused (8 ml/min) at 37°C with modified standard Tyrode 
solution (mM: 118 NaCl, 5 KCl, 2 CaCl2, 1.2 MgSO4, 25 NaHCO3-, 11 
glucose, 0.1 EDTA).  EDTA was used to chelate any trace contaminant 
heavy metals.  The solution was circulated through the bath from an 
unsealed reservoirs through which a mixture of 95% O2 and 5% CO2 was 
bubbled (flow rate: 0.5 L/min) to maintain a pH of 7.4±0.05.  The tendinous 
end of the papillary muscle was attached to a Grass FT03 force transducer 
(Grass Instruments, Quincy, MA, USA) while the other end of the muscle was 
pinned to the bottom of the tissue bath.  The muscle was adjusted to the 
lowest resting length at which maximum twitch force was obtained and field-
stimulated using a Grass S44 stimulator (Grass Instruments, Quincy, MA, 
USA) at 120% of stimulus threshold at 0.5 Hz for 60 min for stabilization.  
After a 15-min rest, a rested-state (RS) contraction was elicited followed by 
stimulation rates of 0.1 Hz, sequentially.  At 0.1 Hz stimulation rate, the 
duration of stimulation was preset and kept constant during the experiment.  
Effects on contractile function were estimated from the peak force and 
maximum rate of force development (dF/dt-max). 
B.  Experimental protocols 
 Cumulative concentration-response curves for isoproterenol as well as 
for forskolin (adenylate cyclase activator) and 3-isobutylmethylxanthine 
(IBMX) [non-selective inhibitor of phosphodiesterase (PDE)] were obtained 
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by increasing the concentration stepwise.  Following baseline measurements 
after a 10-min rest period, drug concentration was increased after muscle 
response had been attained with the previous concentration.  Exposure to 
each drug concentration was maintained for 10 min before recording 
responses.  To examine the potentiating effect of naloxone, a second 
cumulative concentration-response curve was obtained for these three drugs in 
the presence of naloxone (30 µM).  Naloxone was left in contact with the 
tissue for 10 min before obtaining the second concentration-response curve.  
Recovery responses were measured following a 20-min wash. 
 To further confirm the enhancement of contraction by naloxone in the 
presence of isoproterenol as well as forskolin and IBMX, increasing 
concentrations of naloxone in the presence of EC50 values of these drugs were 
applied sequentially.  Recovery responses were measured following a 20-min 
wash. 
  Since both forskolin and IBMX are not water-soluble, we used 
dimethyl sulfoxide (DMSO) to dissolve these compounds.  To exclude the 
effect of DMSO on contractility, appropriate concentrations of DMSO (1-10 
µM), used in the cumulative concentration-response curve for forskolin, were 
applied.  Recovery responses were measured following a 20-min wash. 
As the muscles exposed to isoproterenol as well as forskolin and IBMX 
developed frequent ectopic beats or fatigue at stimulation rates greater than 
0.1 Hz, we measured contractile forces only at RS and 0.1 Hz stimulation rate.  
Each preparation was exposed to only one drug.  As the dF/dt-max value was 
more stable than that of peak force, we used dF/dt-max at 0.1 Hz stimulation 
rate as the measure of contractility in the results. 
After each experiment, the cross-sectional area of each muscle was 
estimated from the muscle length, weight, and density (1.04 g/ml) assuming a 
cylindrical form.  The mean cross-sectional area was 0.67±0.04 mm2 (n=73). 
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2. Effects on tissue levels of cAMP 
 To examine whether naloxone-induced potentiation of the inotropic 
effect of isoproterenol is due to changes in tissue levels of cAMP, we 
investigated whether naloxone could modify the concentration of cAMP in 
stimulated GP myocardium. 
A. Myocardial membrane preparation and quantitative analysis   
 Hearts were excised from male GPs (250-300 g) anesthetized with 
sevoflurane at 3-4 vol%.  Blood was evacuated and hearts were kept in 
ice-cold buffer (0.25 M sucrose, 5 mM Tris/HCl, 1 mM MgCl2; pH 7.4) 
aerated with 100% O2.  Atrium, aorta, and other extraneous tissues were 
removed.  Two hearts were homogenized with 5 volumes of ice-cold 
buffer, transferred into a 15 ml conical tube, and centrifuged at 600 g for 
10 minutes at 4 .  The supernatant was divided into 6℃ -8 1.5 ml 
microcentrifuge tubes and centrifuged at 15,000 g for 10 minutes at 4 .  ℃
The supernatant was centrifuged again at 100,000 g for 60 minutes at 4 .  ℃
The membrane pellet was dissolved in 1 ml of ice-cold incubation buffer 
(mM: 50 Tris/HCl, 10 MgCl2; pH 7.5) and used for quantitative analysis.  
Quantitative analysis was performed with Biochronic Acid Assay (BCA) 
kit (Pierce, Rockford, IL, USA).  Protein concentration was measured by 
the method of Lowry,14 using a bovine serum albumin (0, 0.25, 0.5, 0.75, 
1.0 mg/ml). About 3-4 mg/ml of membranous protein was achieved and 
kept at -20  after freezing with liquid nitrogen. ℃  
B.  Measurement of cAMP concentration   
 Each of 30, 100, 300 µM naloxone, 0.05 µM L-isoproterenol or 
1.35 µM forskolin and the membranous protein (250 µg) were added to 
cAMP production buffer (mM: 2.5 Na2ATP, 5 MgCl2, 1 Tris-EGTA, 20 
creatine phosphate, 50 U/ml creatine phosphokinase, 0.8 IBMX, 50 
Tris/HCl, pH 7.5) in a total volume of 500 µL.  To exclude the effect of 
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DMSO on cAMP levels, the concentrations of DMSO used for the 
forskolin and IBMX cumulative concentration-response curves were also 
tested.  After a 10-min incubation at 37℃, the reaction was stopped with 
100  ℃ heat and the sample was centrifuged at 6,000 g for 20 minutes at 
4 .  The ℃ cAMP concentration in the supernatant was measured using a 
cAMP assay kit [cAMP Biotrak Enzymeimmunoassay (EIA) System, 
Amersham, UK].   
 Working standard was prepared using the standard for acetylation 
assay, anti-serum, cAMP peroxidase conjugate and wash buffer provided 
by cAMP assay kit.  Samples were diluted 100 times in assay buffer [0.05 
M sodium acetate (pH 5.8), 0.02% bovine serum albumin, 0.01% 
preservative].  Acetylation reagent mixed with 2 volumes of 
triethylamine and 1 of acetic anhydride was added to all standards (0-128 
fmol) and samples.  One hundred µL of cAMP antiserum was added to 96 
well plates coated with secondary antibody (except blank and non-specific 
binding wells) and 50 µL of samples or acetylation standard were added to 
each well.  Assay buffer alone (150 µL) was added to non-specific 
binding wells.  Plates were incubated for 60 minutes at 4 . ℃  cAMP 
peroxidase conjugate (100 µL) were added to all wells except blanks and 
plates were incubated for 60 minutes at 4 .  ℃ Wells were aspirated and 
washed 4 times with 400 µL wash buffer and TMB substrate (150 µL) was 
added.  After 1-hour shaking at room temperature, the reaction was 
stopped with 1 M sulfuric acid (100 µL).  cAMP concentration was 
measured at 450 nm with a spectrophotometer (ELISA READER, 
BERSAmax, Molecular devices, Union city, CA, USA).  The experiment 
was performed in duplicate.   
    
3. Electrophysiologic studies  
A.  Isolation of ventricular myocytes   
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 Hearts were quickly excised from male GPs (250-300 g) anesthetized 
with sevoflurane at 3-4 vol% and retrogradely perfused using a Langendorff 
perfusion system.  Hearts were perfused at a rate of 7 ml/min for 5 min at 
37ºC with modified Tyrode solution (mM: 143 NaCl, 5.4 KCl, 1.8 CaCl2, 0.5 
MgCl2, 5 HEPES, 0.18 glucose, pH 7.4).  The perfusate was then switched 
for 5 min to a nominally Ca2+-free Tyrode solution followed by perfusion with 
the same solution to which collagenase (0.4 mg/ml, Worthington type II, 
Worthington Biochemical Corporation, Lakewood, NJ, USA) and protease 
XIV (0.04 mg/ml, Sigma-Aldrich Co., St. Louis, MO, USA) had been added.  
Following a 10-12-min enzymatic treatment, Kraftbrühe solution (mM: 10 
taurine, 10 oxalic acid, 70 glutamic acid, 35 KCl, 10 H2PO4, 11 glucose, 0.5 
Ethylene glycol-bis (β-aminoethyl ether)-N, N, N, N-tetraacetic acid (EGTA), 
10 HEPES, pH 7.4) was perfused for 5 min.  Ventricles were then cut off, 
minced with scissors, and agitated in a small beaker with Kraftbrühe solution.   
The resulting slurry was filtered through a 200-µm nylon mesh.  Isolated 
ventricular cells were stored in Kraftbrühe solution for 1 hr at room 
temperature (21-22°C), then kept at 4ºC and used within 8 hours.  Only rod-
shaped cells with apparent striations that remained quiescent in solution 
containing 1 mM CaCl2 were used.  All the patch clamp experiments were 
carried out at room temperature. 
B.  Electrophysiological techniques  
 Isolated myocytes were allowed to settle to the bottom of a recording 
chamber mounted on an inverted microscope for approximately 10 minutes 
where the bathing solutions could be exchanged.  The chamber was 
continuously perfused at a rate of 2 ml/min.  Standard whole cell voltage-
clamp methods were used.15 Following the initiation of the whole-cell 
recording configuration, an interval of 4-6 min was allowed to establish a 
stable baseline.  Voltage clamp measurements were performed using an 
Axopatch 200B patch clamp amplifier (Axon Instruments, Foster city, CA, 
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USA).  Patch electrodes were prepared from a borosilicate glass model 
KIMAX-51 (American Scientific, Charlotte, NC, USA), which typically have 
a 2-3 MΩ resistance when filled with internal solution.  After fabrication 
with a two-stage micropipette puller, the pipette tips were heat-polished with a 
microforge.  Data acquisition was performed using a pCLAMP system 
version 6.0.3 (Axon Instruments, Foster city, CA, USA) coupled with a 
Pentium-III personal computer.  
C. Voltage-clamp protocols  
 The action potential (AP) was elicited in current-clamp mode by 5-ms, 
800 pA current injections at a frequency of 1 Hz.  To evaluate the effect of 
naloxone on delayed outward K+ current (IK), the IK was measured by step 
depolarizations from -30 to +80mV with a holding potential of -40 mV in 20 
mV increments, 5-s intervals, and 4-s pulse duration.  The effect on inward 
rectifier K+ current (Ik1) was verified by measuring the Ik1 by step 
depolarizations from -140 mV to 0 mV from a holding potential of -40 mV in 
20 mV increments.  Pulses were applied for 200 ms at 5-s.  Voltage-
dependent L-type Ca2+ current (ICa, L) was evoked by 200 ms step 
depolarizations from a holding potential of -40 mV to +10 mV in one step at a 
frequency of 0.1 Hz. 
D.  Solutions   
 An external bathing solution (mM: 140 NaCl, 5.4 KCl, 1 CaCl2, 1 
MgCl2, 5 HEPES, 10 glucose, adjusted to pH 7.4 with 1 N NaOH) was used 
before establishing whole-cell recording.  For K+ current measurements, a 
patch pipette solution (mM: 20 KCl, 110 K-aspartate, 10 EGTA, 10 HEPES, 1 
MgCl2, 5 K2ATP, 1 CaCl2, 10 NaCl, adjusted to pH 7.2 with KOH) was used 
before establishing the whole-cell recording configuration.  After 
establishing the whole-cell voltage clamp, 0.2 mM CdCl2 was added to the 
external bathing solution to eliminate any confounding Ca2+ current.  Inward 
Ca2+ currents were measured using a patch pipette solution (mM: 30 CsCl, 
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100 aspartic acid, 100 CsOH, 10 BAPTA, 10 HEPES, 10 phosphocreatinine, 1 
Na2GTP, 5 Na2ATP, 10 glucose, 2 MgCl2, adjusted to pH 7.25 with 1 M 
CsOH).  Upon obtaining whole-cell recording, the external bathing solution 
was exchanged to a solution (mM: 140 NaCl, 5.4 CsCl, 2 CaCl2, 1 MgCl2, 10 
HEPES, adjusted to pH 7.4 with 1 M CsOH) to measure ICa, L.   
After the baseline measurement with isoproterenol (0.05 µM) in the 
presence of ascorbic acid (1 mM) to prevent oxidation, myocytes were 
exposed to naloxone (30 µM) for 2 minutes.  Recovery responses were 
measured after a 2-min wash.  A 2-min application of naloxone was 
sufficient to produce a stable and consistent effect in pilot experiments. 
 
4. Drugs and chemicals 
 Isoproterenol, forskolin, IBMX, and naloxone (l-form) were obtained 
from Sigma-Aldrich Chemicals Company (St. Louis, MO, USA).  The 
cAMP assay system was obtained from Amersham International, UK.  
Unless otherwise stated, all other chemicals were purchased from Sigma-
Aldrich Chemicals Company. 
Isoproterenol was dissolved in normal Tyrode solution.  Forskolin 
and IBMX were dissolved in DMSO.  
 
5. Statistical analysis 
In papillary muscle and isolated myocyte experiments, repeated measures 
of ANOVA followed by Student-Newman-Keuls test were applied to test for 
statistically significant differences among the baseline, drug application, and 
washout period as well as among the stimulation rates.  One-way ANOVA 
followed by Student-Newman-Keuls test was used to compare the cAMP 
concentrations among each concentration of naloxone.  All results were 
expressed as mean±SEM.  A P value less than 0.05 was considered 
significant. 
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Ⅲ. RESULTS 
 
1.  Effects on contractility 
A.  Effects of isoproterenol and naloxone  
 Isoproterenol (0.01–2 µM) increased contractile forces in a 
concentration-dependent manner, producing a maximal effect at 0.5 µM 
concentration (n=8).  In the presence of naloxone (30 µM), isoproterenol 
increased contractile forces in a concentration-dependent manner, producing a 
maximal effect at the same concentration (n=6).  Naloxone (30 µM) 
produced a leftward shift of the isoproterenol concentration-response curve 
and reduced the EC50 from 0.05±0.02 µM for isoproterenol alone to 0.02±0.01 
µM in the presence of naloxone (Fig. 1A).  Despite the visible leftward shift, 
the EC50 values at the same isoproterenol concentration were not statistically 
different.  Baseline values of isoproterenol (0.01 µM) in the absence and 
presence of naloxone at 0.1 Hz stimulation rate were 4.76±1.36 and 
10.94±4.76 mN/s/mm2, respectively. 
 In preliminary experiments using 10 and 30 µM naloxone to verify its 
enhancement of contractile forces by naloxone in the presence of 
isoproterenol (0.03 µM), we observed that 10 and 30 µM naloxone increased 
contractile force by 28±6% (n=6, P<0.05) and 45±8% (P<0.05), respectively, 
when compared to that of isoproterenol alone (Fig. 1B).  Complete recovery 
was shown following a 20-min wash with isoproterenol. 
 Sequential application of naloxone (30, 100, and 300 µM) in the 
presence of EC50 isoproterenol increased contractile forces by 33±9% 
(P<0.05), 49±13% (P<0.05), and 69±13% (P<0.05), respectively, when 
compared to those induced by EC50 isoproterenol (n=6).  Similar contractile 
enhancement was shown between 30 and 100 µM naloxone, while 300 µM 
caused a significant increase in contractility when compared to that of 30 µM 
(Fig. 1C).  Complete recovery was shown following a 20-min wash with 
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Fig.1.  Naloxone potentiation of the positive inotropic effect of isoproterenol 
in isolated guinea pig ventricular myocardium.  A.  Isoproterenol 
cumulative concentration-response curves of isoproterenol in the absence 
(n=8) and presence of naloxone (NAL) (30 µM) (n=6).  Inotropic responses 
are expressed as a percentage of baseline in the absence of isoproterenol.  
Each point represents the mean value±SEM.  B.  Effects of naloxone on the 
contractile forces at 0.1 Hz stimulation rate in the presence of isoproterenol 
(0.03 µM) (n=6).  dF/dt-max indicates maximum rate of force development 
per cross sectional area.  Error bars indicate SEM.  *; P<0.05 versus control.  
C.  Effects of higher concentrations of naloxone on the contractile forces at 
0.1 Hz stimulation rate in the presence of EC50 isoproterenol (0.05 µM) (n=6).  
dF/dt-max indicates maximum rate of force development per cross sectional 
area.  Error bars indicate SEM.  *; P<0.05 versus control.  †; P<0.05 
versus 30 µM concentration. 
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isoproterenol. 
B.  Effects of forskolin and naloxone  
 To examine whether naloxone modifies the effect of forskolin, 
cumulative concentration-response curves were obtained in the absence (n=9) 
and presence of naloxone (30 µM) (n=8).  Forskolin (0.5–30 µM) produced a 
concentration-dependent increase in contractile forces, producing maximal 
contractile force at 10 µM.  While naloxone (30 µM) produced a leftward 
shift of the forskolin concentration-response curve between 0.5 and 3 µM, 
marked enhancement of contraction was observed from 10 to 30 µM.  EC50 
values of forskolin in the absence and presence of naloxone was 1.35±0.17 
and 1.63±0.42 µM, respectively (Fig. 2A), which showed no difference (NS).  
Baseline values of forskolin (0.5 µM) in the absence and presence of naloxone 
were 7.80±1.54 and 9.94±2.54 mN/s/mm2, respectively. 
 Application of 10 and 30 µM naloxone in the presence of EC50 
forskolin increased contractile forces by 33±10% and 88±26% (P<0.05) when 
compared to that of EC50 forskolin alone, respectively (n=6).  Complete 
recovery was shown following a 20-min wash (Fig. 2B).  
C.  Effects of IBMX and naloxone  
 To examine whether naloxone modifies the effect of IBMX, 
concentration-response curves for IBMX were obtained in the absence and 
presence of naloxone (30 µM).  Either IBMX (50-400 µM) alone (n=7) or in 
the presence of naloxone (30 µM) (n=8) produced a concentration-dependent 
increase in contractile forces.  Application of IBMX in the presence of 
naloxone did not shift the concentration-response curve obtained in the 
absence of naloxone (NS).  The EC50 IBMX (108.84±0 µM) was similar to 
that in the presence of naloxone (103.30±0 µM) (NS) (Fig. 3A).  Baseline 
values of IBMX (50 µM) in the absence and presence of naloxone were 
9.35±3.48 and 3.97±1.68 mN/s/mm2, respectively. 
 Application of 10 and 30 µM naloxone in the presence of EC50 IBMX  
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Fig. 2.  Naloxone potentiation of the positive inotropic effect of forskolin 
(FSK) in isolated guinea pig ventricular myocardium.  A.  Forskolin 
cumulative concentration-response curves of forskolin in the absence (n=9) 
and presence of naloxone (NAL) (30 µM) (n=8).  Inotropic responses are 
expressed as a percentage of baseline in the absence of forskolin.  Each point 
represents the mean value±SEM.  B.   Effects of naloxone on the 
contractile forces at 0.1 Hz stimulation rate in the presence of EC50 FSK (1.35 
µM) (n=4).  dF/dt-max indicates maximum rate of force development per 
cross sectional area.  Error bars indicate SEM.  *; P<0.05 versus control. †; 
P<0.05 versus forskolin. 
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Fig. 3.  Naloxone effects on the positive inotropic effect of 3-
isobutylmethylxanthine (IBMX) in isolated guinea pig ventricular 
myocardium.  A.  IBMX cumulative concentration-response curves in the 
absence (n=7) and presence of naloxone (NAL) (30 µM) (n=8).  Inotropic 
responses are expressed as a percentage of baseline in the absence of IBMX.  
Each point represents mean value±SEM.  B.   Effects of naloxone on the 
contractile forces at 0.1 Hz stimulation rate in the presence of EC50 IBMX 
(108 µM) (n=4).  dF/dt-max indicates maximum rate of force development 
per cross sectional area.  There was no potentiating effect of naloxone in the 
presence of EC50 IBMX.  Error bars indicate SEM. 
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did not alter the contractile forces when compared to that of EC50 IBMX alone 
(N=4, NS).  Complete recovery was shown following a 20-min wash (Fig. 
3B).   
 DMSO (1, 3, and 10 µM) did not alter the contractile forces (N=6, NS) 
(control: 7.55±1.81; 1 µM: 6.80±1.77; 3 µM: 6.78±1.88; 10 µM: 6.30±1.8 
mN/s/mm2).  In preliminary experiments, we also confirmed that DMSO (30 
µM) (n=2) did not alter the contractility (control: 10.97±4.93; 1µM: 
10.97±4.93 mN/s/mm2).  In the cumulative concentration-response curves, 
the maximal concentrations of DMSO for forskolin (30 µM) and IBMX (400 
µM) in the reservoir solution (200 ml) was 2% and 1.33% by volume, 
respectively. 
 
II. Effects of isoproterenol, forskolin, and naloxone on the tissue level of 
cAMP 
 While the production of cAMP stimulated by the EC50 isoproterenol 
(0.05 µM) increased by approximately 2-fold of the basal level (n=8, P<0.05), 
application of each concentration of naloxone (30, 100, and 300 µM) did not 
alter the level of cAMP (n=8, NS) (Fig. 3A).  Whereas EC50 forskolin (1.35 
µM) produced a 4-fold increase in basal level of cAMP, each concentration of 
naloxone (30, 100, and 300 µM) did not alter the level of cAMP (n=6, NS) 
(Fig. 3B).  The vehicle, DMSO (1-10 µM), did not produce any change in 
tissue level of cAMP (n=8, NS) (control: 452±177; 1µM: 488±186; 3 µM: 
489±183; 10 µM: 356±99 fmol/mg protein).   
 
III.  Electrophysiologic study 
 Fig. 5 shows prolongation of AP duration by naloxone (30 µM) in the 
presence of EC50 isoproterenol in a GP ventricular myocyte.  Naloxone (30 
µM) prolonged the APD50 and APD90 by 27±8% (P<0.05) and 26±8% 
(P<0.05), respectively, following application of the EC50 isoproterenol (n=5). 
 - 18 - 
 
 
Fig. 4.  Effects of isoproterenol (ISO) and forskolin (FSK) on tissue cAMP 
levels in the absence and presence of naloxone.  A.  Naloxone cumulative 
concentration effects in the presence of EC50 ISO (0.05 µM) (n=8).  B.  
Effects of cumulative concentration effect in the presence of EC50 FSK (1.35 
µM) (n=6).  Error bars indicate SEM.  *; P<0.05 versus control. 
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The AP amplitude and resting membrane potential remained unaltered.  AP 
duration was partially restored to baseline level following a 2-3 min wash 
(Table 1).   
 Peak outward IK assessed at +80 mV was reduced by 20±3% (n=13, 
P<0.05) by naloxone (30 µM) in the presence of isoproterenol when 
compared to that of EC50 isoproterenol alone (2.0±0.18 nA).  Peak outward 
IK was not restored to the baseline level (57±9% of the baseline) following 
washout (Fig. 6). 
 At membrane potential ranges from -140 mV to 0 mV, naloxone (30 
µM) in the presence of EC50 isoproterenol did not alter the inward and 
outward components of IKI (n=5, NS) (Fig. 7A, B).   
 At a membrane potential of +10 mV, naloxone (30 µM) in the presence 
of EC50 isoproterenol reduced the ICa, L by 28±3% (n=8, P<0.05) when 
compared to that of EC50 isoproterenol alone (0.75±0.09 nA) (Fig 8A, B).  
The effect of naloxone on ICa, L was not reversible following a 2-3 min wash.  
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Fig. 5.  Effects of naloxone (30 µM) on the action potential in the presence 
of EC50 isoproterenol (0.05 µM) in a guinea pig ventricular myocyte.  The 
dotted line indicates recovery following a 2-3 min wash.  C indicates control 
in the presence of isoproterenol. 
 
 
 
 
Fig. 6.  Effect of naloxone (30 µM) on the delayed outward K+ current (Ik) in 
the presence of EC50 isoproterenol (0.05 µM) in a guinea pig ventricular 
myocyte.  Control current was obtained in the presence of EC50 isoproterenol.   
Ik was measured by step depolarizations from -30 to +80 mV from a holding 
potential of -40 mV in 20 mV increments over 5-s intervals.  The dotted line 
indicates zero current level.  
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Fig. 7.  A.  Effects of naloxone (30 µM) on the inward rectifier K+ current 
(Ik1) in the presence of EC50 isoproterenol (0.05 µM) in guinea pig ventricular 
myocytes.  Control current was obtained in the presence of EC50 value of 
isoproterenol.  The dotted line indicates recovery following a 2-3 min wash.  
Ik1 was measured by step depolarizations from -140 mV to 0 mV from a 
holding potential of -40 mV in 20 mV increments.  The pulse was applied for 
200 ms at 5-s intervals.  Error bars indicate SEM.  B.  A representative 
tracings in a guinea pig ventricular myocyte.  
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Fig. 8.  Effects of naloxone (30 µM) on L-type Ca2+ current in the presence 
of EC50 isoproterenol (0.05 µM) in a guinea pig ventricular myocyte.  
Unfilled circles indicate peak current of an individual record.  The horizontal 
bar indicates the period when naloxone was applied.  (Inset) An example of 
individual currents recorded in the presence of naloxone. 
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Table 1. Effects of Naloxone (30 µM) in the Presence of Isoproterenol (0.05 
µM) on the Normal Action Potential 
       RMP          AMP       APD50    APD90 
Control -66 ± 4 119 ± 3 823 ± 60  847 ± 58 
Naloxone -66 ± 4 118 ± 3 1032 ± 68 * 1005 ± 65* 
Recovery -63 ± 5 118 ± 3         912 ± 46 *  938 ± 45* 
 
Results are presented as mean±SEM.  Repeated measures analysis of 
variance followed by Student-Newman-Keuls test was used to test for 
differences among groups.  RMP = resting membrane potential; AMP = 
action potential amplitude; APD50 and APD90 = the duration of the action 
potential at 50% and 90% of depolarization, respectively.  *; P<0.05 versus 
control.  
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Ⅳ. DISCUSSION 
 
The present results demonstrate that naloxone potentiates the positive 
inotropic response elicited by isoproterenol in the isolated GP papillary 
muscles.  In the presence of isoproterenol, naloxone modestly, but 
significantly, reduced the delayed outward K+ current, resulting in 
prolongation of AP duration which contributes to potentiation of the positive 
inotropic response induced by isoproterenol secondary to more enhanced Ca2+ 
entry by naloxone.  Naloxone appeared to have no effect on tissue cAMP 
levels elicited by pretreatment with either isoproterenol or forskolin.  
 It is postulated that, during shock, ß-endorphins from the anterior 
pituitary are released into the systemic circulation16 and bind to opiate 
receptors in the heart.17,18 These receptors interact with inhibitory G-protein 
complexes which subsequently inhibit the adenylate cyclase activity and 
attenuate the increases in intracellular cAMP levels normally produced by ß-
adrenergic receptor stimulation.  In this model, when naloxone is 
administered, the endorphins are displaced from opiate receptors in the 
myocardium, and, with removal of the opiate effect, the normal response to ß-
adrenergic agonists is restored.9 
 Naloxone’s action mediated by opiate receptors during shock is 
supported by evidence that l-naloxone, but not d-naloxone, is effective at 
increasing myocardial function when delivered directly into the coronary 
circulation of dogs subjected to hemorrhagic shock.19 However, these results 
are in conflict with those of Caffery et al. using isolated canine renal 
arteries,12 who showed that potentiation of the adrenergic effect was not 
stereo-specific.  Such a non stereo-specific effect of naloxone has also been 
demonstrated in dogs using in situ-isolated heart/lung preparation.13 Lechner11 
in a study using GP papillary muscles proposed that naloxone has more than 
one site of action, suggesting non-opiate receptor-mediated interaction 
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between naloxone and isoproterenol.  He demonstrated that, at low 
concentration of naloxone (0.1 µM), the beneficial non-opiate receptor-
mediated properties of l-naloxone are attenuated by its concurrent action at 
opiate receptors.  However, at higher concentrations (10 or 30 µM), d- and l-
naloxone showed similar increase in contractility, indicating that the non-
opiate receptor-mediated properties of l-naloxone predominate.  Non-opiate 
receptor-mediated action of l-naloxone in the presence of ß-agonists has also 
been demonstrated in dogs using renal artery12 and in situ isolated heart-lung 
preparation.13  
 Lechner,11 demonstrated that application of 10 and 30 µM l-naloxone 
to GP ventricular tissues potentiated the positive inotropic effect of 
isoproterenol by approximately 20% and 32%, respectively.  In the 
preliminary experiment using the same animal preparation, we confirmed that 
naloxone potentiated contractility in the presence of isoproterenol (Fig 1B).  
In another experiment using the EC50 isoproterenol, we also observed that 30 
and 100 µM naloxone increased contractility by 33±9% and 49±13%, 
respectively (Fig. 1C).  Kim et al.20 in their study assessing the direct 
myocardial depression by naloxone alone demonstrated that naloxone (50 
µM) depressed contractility in GP ventricular tissues by approximately 20%, 
suggesting little effect at 30 µM.  Based on the concentrations used by 
Lechner11 and Kim et al.,20 we decided that 30 µM concentration would be 
appropriate to use in further experiments because naloxone alone had little 
effect on contractility 
 We observed the maximum contraction above 0.5 µM concentration in 
the isoproterenol cumulative concentration-response curve, which indirectly 
suggests that production of cAMP induced by isoproterenol at this 
concentration is maximal.  Furthermore, naloxone did not enhance the 
contractile force above 0.5 µM, suggesting full saturation of the increased 
cAMP levels.  In the forskolin cumulative concentration-response curve, 
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maximal contractile force was reached above 10 µM concentration, which 
suggests that maximal cAMP is produced by forskolin alone.  Interestingly, 
however, contraction was markedly enhanced above 10 µM in the naloxone-
pretreated group, suggesting that there may be another non-opiate receptor-
mediated mechanisms in addition to the inhibitory effect on Ik.  Of the 
possible alternatives, inhibitory effect on Na/K pump as well as on Na+-Ca2+ 
exchange pump, which contributes to the myocardial contraction, has been 
investigated.  Levin et al.21 in their study using rat left atria and strips of 
ventricular muscles suggested inhibition of the sarcolemmal Na/K pump by 
naloxone, which contributes to the concentration-dependent positive inotropic 
effect from 10 to 500 µM concentration ranges.  Inhibition of Na+-Ca2+ 
exchange by high concentrations of naloxone (IC50: 4,000 µM) in isolated calf 
cardiac sarcolemmal vesicles has also been proposed, indicating negligible 
inhibition of Na+/Ca2+ exchange activity in the concentration range of 30-300 
µM which we used in this study.22 Levin et al.21 also suggested that naloxone 
has no effect on Na+-Ca2+ exchange pump function.  
 ß-agonists bind to ß-adrenergic receptors in the cardiac membrane.  
This receptor-ligand complex binds to stimulatory guanine nucleotide-binding 
proteins.  These activate adenylate cyclase, which converts ATP to cAMP, 
the second messenger for inotropic responses to catecholamine.  To examine 
whether the naloxone-induced potentiation of isoproterenol-induced inotropic 
effects elicited under our experimental conditions is due to the changes in 
tissue cAMP levels, we investigated whether naloxone could modify the 
stimulated concentration of cAMP.  Our results showed that naloxone does 
not alter the increased cAMP levels elicited by pretreatment with ß-agonist.  
We also examined the possibility that naloxone facilitates the effect of 
isoproterenol on adenylate cyclase by increasing cyclic AMP production.  To 
this purpose, we examined the interaction between forskolin and naloxone.  
Forskolin is an activator of the catalytic subunit of adenylate cyclase and 
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increases cyclic AMP production by this mechanism.21 Our results showed 
that naloxone has no effect on forskolin-induced cAMP levels.  We had 
initially hypothesized that naloxone would enhance isoproterenol-induced 
increases in cAMP level, resulting in potentiation of the inotropic effect of 
isoproterenol.  However, unexpectedly, naloxone did not alter the cyclic 
AMP production induced by EC50 isoproterenol or forskolin even though it 
significantly enhanced contraction, as shown in our contraction experiments.  
It is well established that catecholamine enhances myocardial contractility by 
increasing intracellular cAMP levels, and this response is amplified by the 
presence of PDE inhibitor, IBMX,23,24 a prototype of non-selective PDE 
inhibitor.25  In this study, addition of naloxone did not alter the cumulative 
concentration-dependent contractility, which indicates that naloxone has no 
effect on the enzyme cyclic nucleotide PDE.    
 Since both forskolin and IBMX are not water-soluble, we used DMSO 
to dissolve these compounds.  DMSO has been reported to show some 
pharmacological activity in several tissues.26,27 In the innervated GP cardiac 
atrial tissue, 3% DMSO produced a moderate increase in contractility, which 
became very marked when the final bath concentration was 6%.28 In our 
experiments with GP ventricular tissue, the maximal concentration of DMSO 
in the reservoir (200 ml Tyrode solution) was about 2%, which showed no 
alteration of contraction and cAMP levels.  Therefore, it is likely that 
naloxone’s potentiating effect on contraction in the presence of forskolin or 
IBMX could not be attributed to its solvent DMSO.  
 In GP ventricular myocytes, we observed that naloxone (30 µM), in the 
presence of isoproterenol, significantly prolonged AP duration.  Naloxone 
alone has also been reported to prolong the AP duration in GP20,29 and rabbit30 
cardiac tissues with little effect on the resting membrane potential.  In rat 
ventricular myocytes, naloxone (3-30 µM) prolonged AP duration in a 
concentration-dependent manner, and a similar effect was shown in GP and 
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human atrial cells at 10 µM.31 Increased plateau phase due to prolonged AP 
duration may permit enhancement of Ca2+ entry, resulting in increased
 
contractile force.  However, our whole cell voltage clamp experiments 
revealed a reduction of peak Ice, L by naloxone in the presence of isoproterenol, 
which highly
 
suggests an effect on the repolarizing K+ currents.  
 Brasch29 in his study using GP atrial and ventricular tissues indirectly 
suggested inhibition of K+ outward current as a cause of prolongation of AP 
duration by naloxone (30-120 µM) alone.  Kim et al.20 also demonstrated AP 
prolongation by naloxone (100 µM) alone and suggested direct inhibition of 
K+ current in GP ventricular myocardium.  In other tissues, inhibition of the 
membrane K+ conductance in frog node of Ranvier32 and in squid axons33 has 
also been demonstrated.  Based on these suggestions and evidences, we 
speculated that naloxone could affect the repolarizing K+ currents.  In the 
present study, whole cell voltage clamp experiments revealed that naloxone 
suppresses the slowly activating current, Ik.  Considering the higher voltage 
used in this study, at which a rapidly activating, inward rectifier current, Ikr, is 
usually deactivated, the effects of naloxone primarily represent depression of 
Iks.  Ik is composed of two different current types: a rapidly activating, 
inward rectifier current, Ikr, and a slowly activating current, Iks.34  Inhibition 
of delayed outward K+ current (28.3±4.5%) by naloxone (10 µM) alone in GP 
atrial cells at 37°C, similar to the extent of reduction in our results, has also 
been reported.31   
 The inward rectifier K+ current is the primary current responsible for 
maintaining a stable cardiac resting membrane potential near the K+ 
equilibrium potential.  Inhibition of Ik1 can result in diastolic depolarization, 
which in turn can cause increase cardiac excitability35 and lead to 
dysrhythmias due to abnormal automaticity.36 The lack of change in the 
resting membrane potential following application of naloxone (30 µM) may 
be attributable to the lack of alteration of Ik1.  In addition to the inward 
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current, Ik1 also contributes to the terminal phase of repolarization via outward 
current at potentials from -50 or -40 mV to 0 mV.30,37 Whereas our results 
demonstrated little alteration of Ik1 by naloxone from -140 mV to 0 mV, Hung 
et al.31 observed increase of inward component of Ik1 by 10 µM naloxone, 
approximately 20%, with no alteration of outward component of Ik1 in rat 
ventricular myocytes.   
 Our whole cell voltage clamp experiments revealed a reduction in peak 
ICa, L despite the prolonged of AP duration.  Although inhibition of ICa, L can 
lead to a reduction of AP duration, the reduction of Iks seems to have a greater 
effect, resulting in AP lengthening in the present study.   
 Non-opioid receptor-mediated effect of naloxone alone on the AP as 
well as contraction has also been proposed in rabbit ventricular tissue and 
arterially perfused interventricular septa,38 in GP atrial and ventricular 
myocardium,29 and in rat heart.39   
 Naloxone alone (50, 100, and 200 µM) causes a concentration-
dependent depression of contractile force in GP ventricular tissues,20 By 
contrast, in our results, sequential administration of naloxone (30, 100, and 
300 µM) in the presence of isoproterenol showed concentration-related 
enhancement of contractile forces.  Considering that the potential mechanism 
behind these opposite results could be the same, non-opiate receptor-mediated 
effect, it is quite perplexing that the effects on contraction are opposite.  In 
GP ventricular tissues, naloxone (100 µM) alone caused prolongation of 
APD50 and APD90 by approximately 12%.20 Based on this, we may assume 
that the changes in AP duration are minimal or negligible at 30 µM 
concentration, and produce little effect on repolarizing K+ current so that the 
reduction in Ca2+ entry by naloxone, approximately 35% by 50 µM 
concentration,20 predominates, resulting in depression of contractile force.  
In the isoproterenol-pretreated group, however, the intracellular Ca2+ 
concentration may be little affected despite direct inhibition of Ca2+ entry by 
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naloxone (30 µM) because intracellular Ca2+ is already quite abundant by 
prior application of isoproterenol.  Thus, prolongation of AP duration by 
naloxone in the presence of isoproterenol would result in more Ca2+ entry, 
followed by enhanced contraction.   
 In this study, we observed concentration-related enhancement of 
contraction (30, 100, and 300 µM) by naloxone in the presence of 
isoproterenol, in which naloxone (300 µM) significantly increased 
contractility by approximately 70% when compared to that of isoproterenol-
treated group.  Considering that naloxone in the presence of isoproterenol 
prolonged AP duration by 26±8%, one may assume that a higher 
concentration of naloxone (300 µM) may further prolong the AP duration 
secondary to further inhibition of Ik.  This would result in further 
enhancement of contractility via enhanced Ca2+ entry.  Under these 
conditions, as intracellular Ca2+ was already much increased by prior 
administration of isoproterenol, reduction of ICa, L by naloxone (300 µM) may 
have little effect.  In contrast, 200 µM naloxone alone depressed contractility 
by approximately 60% in the same animal preparation.20 Considering the AP-
prolonging effect of naloxone (100 µM) alone, approximately 12%,20 it could 
be assumed that a higher concentration of naloxone (200 µM) may further 
prolong the AP duration, followed by enhanced contractility secondary to 
enhanced Ca2+ entry.  However, naloxone (200 µM) did not increase the 
contractility but instead caused marked contractile depression.  It may be 
speculated that 200 µM naloxone directly reduces Ca2+ entry much more than 
that of 50 µM, and this may overwhelm the Ca2+ entry during the plateau 
phase induced by naloxone’s inhibition of Ik.  Further study will be required 
to validate the effect of high naloxone concentration alone on the ICa, L and 
repolarizing K+ current.   
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Ⅴ. CONCLUSION 
 
In conclusion, the enhancement of myocardial contractility by 
naloxone in the presence of isoproterenol is, at least in part, likely due to 
inhibition of delayed outward K+ current, which results in a secondary 
increase of inward Ca2+ current.  Naloxone-induced potentiation of inotropic 
effects in states of shock may not only be related to reversal of the effects of 
endorphins but also to its direct inotropic action via a non-opiate receptor-
mediated mechanism. 
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< ABSTRACT(IN KOREAN)> 
β-수용체 촉진에 따른 심근 수축력 증가에 대한 naloxone의 
강화 작용: non-opiate 수용체 기전 및 cAMP의 역활 
 
<지도교수 박윤곤> 
 
연세대학교 대학원 의학과 
 
장철호 
 
 본 연구는 심근의 수축력을 항진시키는 효과를 가진 
naloxone의 비아편성수용체 전달반응을 규명하고자 하였다. 심근수
축력 측정, cyclic adenosine monophosphate (cAMP)의 측정, 전기
생리학적인 방법들이 사용되었다.  
 수컷 기니픽 (300-400 g)을 sevoflurane으로 전신마취 한 
상태에서 우심실 유두근(papillary muscle)을 적출하였다. 최대 장력 
및 최대 장력 발생 속도(maximum rate of force development, 
dF/dt-max)로 심근수축력을 평가하였다. Isoproterenol, forskolin, 
isobutylmethylxanthine (IBMX)의 용량을 단계적으로 증가시키며 
용량-반응 곡선을 얻었다. 각각의 isoproterenol, forskolin, IBMX를 
EC50 용량으로 전처치 후 naloxone의 농도를 증가시키면서 수축력
이 항진되는 것을 확인하였다. cAMP의 측정을 위해 기니픽의 심근
을 분쇄하여 균질화한 뒤 원심분리하여 세포막단백질을 분리하였다. 
EC50의 isoproterenol 또는 forskolin 과 함께 naloxone을 투여하
고 naloxone의 농도에 따른 cAMP 농도를 cAMP assay kit을 이용
하여 측정하였다. 전기생리학적인 연구에서는 action potential, 
delayed outward K+ current (Ik), inward rectifier K
+ current (Ik1) 
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와 L-type Ca2+ current (ICa, L)을 측정하였다. 
 Naloxone (30 µM)은 isoproterenol의 용량-반응 곡선을 좌
측으로 이동시켰다. 또한 forskolin의 용량-반응 곡선을 3 µM 까지
는 좌측으로 이동시키고 10에서30 µM의 농도에서는 현저하게 증가
된 수축력을 보였다. 하지만, IBMX의 용량-반응 곡선에는 영향을 
주지 않았다. Isoproterenol의 전처치 후에 10, 30, 300 µM 
naloxone의 점진적인 투여는 용량에 따른 심근수축력의 증가를 보
였다. EC50 용량의 isoproterenol 또는 forskolin과 naloxone을 같
이 투여해도 cAMP의 농도에는 영향이 없었다. Isoproterenol 전처
치 후 naloxone 30 µM은 APD50과 APD90 을 연장시켰으나 크기나 
안정막전위에는 영향이 없었다. Naloxone은 isoproterenol 전처치 
군에서 peak outward Ik를 +80 mV에서 20±3% 감소시켰으나, -
140mV에서 0 mV까지 Ik1에는 영향이 없었다. 또한, Naloxone은 막
전위 +10 mV에서 ICa, L을 28±3% 감소시켰다. 따라서, 
isoproterenol 전처치후 naloxone이 심근 수축을 증가시키는 한 원
인으로서 Ik의 억제에 의한 활동전위의 연장으로 세포내로의 Ca
2+ 
내향 전류가 증가하여 심근 수축이 증가하는 것으로 생각된다.  
-------------------------------------------------- 
핵심되는 말: Naloxone, 비아편성수용체 전달 반응, 심근수축력, 
cAMP, delayed outward K+ current. 
 
